Pyxis Oncology Announces Board Changes and Officer Compensation Updates
Ticker: PYXS · Form: 8-K · Filed: Jun 10, 2024 · CIK: 1782223
| Field | Detail |
|---|---|
| Company | Pyxis Oncology, Inc. (PYXS) |
| Form Type | 8-K |
| Filed Date | Jun 10, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, governance, filing
TL;DR
Pyxis Oncology shakes up its board and exec pay structure. Big changes ahead?
AI Summary
Pyxis Oncology, Inc. announced on June 10, 2024, a series of significant corporate events. These include the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its officers. The company also filed financial statements and exhibits as part of this Form 8-K.
Why It Matters
Changes in a company's board and officer compensation can signal shifts in strategy, governance, or financial health, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board and officer changes, especially without detailed explanations, can introduce uncertainty about the company's future direction and stability.
Key Numbers
- 001-40881 — SEC File Number (Identifies the company's filing with the SEC.)
- 83-1160910 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Pyxis Oncology, Inc. (company) — Registrant
- June 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- Boston, Massachusetts (location) — Principal Executive Offices
FAQ
Who are the specific officers and directors departing Pyxis Oncology?
The filing indicates the departure of 'certain officers' and 'certain directors' but does not name them specifically in the provided text.
Who are the newly elected directors of Pyxis Oncology?
The filing states the election of directors but does not provide their names in the excerpt.
What are the details of the compensatory arrangements for the officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but the specific details are not included in this excerpt.
What specific financial statements and exhibits are being filed?
The filing lists 'Financial Statements and Exhibits' as an item, but the content of these documents is not detailed in the provided text.
What is the significance of the 'Regulation FD Disclosure' item?
This indicates that the company is making public disclosures in compliance with Regulation Fair Disclosure, ensuring that material information is disseminated broadly.
Filing Stats: 828 words · 3 min read · ~3 pages · Grade level 10.3 · Accepted 2024-06-10 07:56:02
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share PYXS The Nasdaq Global Se
Filing Documents
- d843596d8k.htm (8-K) — 28KB
- d843596dex991.htm (EX-99.1) — 9KB
- g843596img1.jpg (GRAPHIC) — 7KB
- 0001193125-24-157911.txt ( ) — 172KB
- pyxs-20240610.xsd (EX-101.SCH) — 3KB
- pyxs-20240610_lab.xml (EX-101.LAB) — 18KB
- pyxs-20240610_pre.xml (EX-101.PRE) — 11KB
- d843596d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated June 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Pyxis Oncology, Inc. Date: June 10, 2024 By: /s/ Pamela Connealy Pamela Connealy Chief Financial Officer and Chief Operating Officer